By Skyepharma Production…
To get in touch with Skyepharma Production S.A.S., simply fill out the form below.
Subscribe to Supplier
Skyepharma brings CDMO expertise in OSD to BIO International in Boston
Lyon, France: – Oral dosage specialist Skyepharma Productions S.A.S. (Skyepharma) is returning to the high prestige BIO International Convention networking event in the USA, this year being held in Boston MA.
Skyepharma will be one of the key members of the Lyonbiopole competitiveness cluster that is driving health innovation in the Auvergne-Rhône-Alpes region, exhibiting as part of the Business France pavilion combined exhibition at Booth 951 at the Boston Convention Center.
Advanced CDMO offerings
Skyepharma’s displays and networking activities will showcase its extensive range of CDMO offerings in advanced oral solid dose development and manufacturing. It will feature its latest capabilities for OSD development and manufacturing, including HPAPI & Oncology formulations, controlled substances and scheduled drugs, treatments for Orphan & Rare Diseases, Modified Release formulations, GIT & colon targeting, Combo APIs, and hard-to-make tabs and caps, including multi-layer tablets.
Skyepharma will also be promoting its various Innovation programs, including the SkyeHub bioproduction center.
The Skyepharma team participating in face-to-face networking and online discussions using the BIO partnering platform will be led by Chief Business Officer Laurent Rigaudeau, supported by Chief Scientific Officer, Dr. Frederic Checot, and Business Development Manager Guillaume Lebel.
M. Rigaudeau commented: “Our experiences with BIO events have been very positive and we are looking forward to attending this superb networking event that will provide us with an excellent platform to meet new prospects and discuss potential partnerships.”
Dr. Checot added: “For the BIO audience that includes many pharma, including virtual and big pharma, early stage R&D companies as well as biotech, seeking a CDMO partner with strong development capabilities in complex solid forms we can offer a very comprehensive portfolio of capabilities and formulation innovations, that includes multilayer tablet, tab-in-tab, controlled release and enhanced bioavailability expertise, as well as tablets in capsules, along with agility, high quality assurance, advanced development capabilities and a one stop shop, end-to-end, business model.” Their innovative business model is also now available in their new “Skyehub Bioproduction™” offer for biotechs.
Skyepharma is an independent French pharmaceutical CDMO, 100% owned by its management team and Bpifrance. Skyepharma is an expert CDMO specialised in the formulation, development and manufacturing of complex oral solid forms (OSD), with an extensive and specific expertise and proprietary technologies on modified release products.
Skyepharma is based in Saint-Quentin-Fallavier, France. The current factory, dedicated to its OSD activity, occupies 22,000m2, on a 60,000m2 piece of land. Skyepharma has decided to allocate a portion of the available land (more than 10,000m2) to establish its SkyeHub Bioproduction, an innovative model designed to offer clinical and commercial production capacities to biotech companies. This SkyeHub model includes the construction of dedicated buildings, with specifically designed surfaces and premises, together with transverse support services such as quality, maintenance, batch release, etc.
Learn more at: www.skyepharma.com
About BIO International 2023
The 30th BIO International Convention (BIO 2023) provides a platform for biotechnology and pharma leaders to discover new opportunities and promising partnerships across a wide spectrum of life science and application areas, including drug discovery, biomanufacturing, genomics, nanotechnology and cell therapy.
Themed ‘Stand Up for Science’, BIO International 2023 is a four -day event opening June 5 at the Boston Convention & Exhibition Center in Massachusetts.
The convention will attract more than 4,000 biotechnology and pharma leaders for a week of intensive networking to discover new opportunities and promising partnerships, with many meetings using the proprietary BIO One-on-One partnering™ system, as well as hundreds of individual company presentations, a program of world-renowned keynote speakers and some 20 Session Tracks.
A co-located trade show will feature more than 1,800 exhibitors from fields ranging from digital health and diagnostics to bioprocesses.
The event is organised by the Washington DC-based Biotechnology Innovation Organisation with more information at: https://www.bio.org/events/bio-international-convention